Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

NCT00722254 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2016-03-21

No results posted yet for this study

Summary

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Josef T Prchal, MD · University of Utah

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722254 on ClinicalTrials.gov